A Feasibility Trial of Everolimus (RAD001),an mTOR Inhibitor, Given in Combination With Multiagent Re-Induction Chemotherapy in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL)
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 15
- 主要终点
- Safety and Feasibility
研究概览
简要总结
Laboratory and other studies suggest that, the study drug, Everolimus (RAD001), may prevent tumor cell growth and also may increase the efficacy of other chemotherapy drugs. Everolimus is approved for use in the United States for certain types of cancer, such as kidney cancer. It has been extensively studied in people with various types of cancer as a single agent (a drug that is used alone to treat the cancer) or in combination with a number of other drugs. Studies in adults with cancer have also evaluated Everolimus in combination with other anti-tumor drugs. Information from lab studies and some other clinical trials suggests that Everolimus may kill leukemia cells on its own, and also make it more likely that steroids (such as prednisone) are able to kill leukemia cells.
In this research study, we are looking to learn more about how Everolimus works in combination with other drugs which are commonly used to treat relapsed acute lymphoblastic leukemia (prednisone, vincristine, PEG-asparaginase, and doxorubicin). The main goal of the study is to evaluate the side effects of this treatment combination in order to determine a safe dose of Everolimus which can be given with these other 4 drugs.
详细描述
Study Treatment: The study treatment lasts 32 days during which time you will be taking the study drug Everolimus daily for 32 days in addition to standard chemotherapy drugs. Below lists the study drug as well as the other drugs you will be receiving to treat your leukemia during this research study.
Chemotherapy drugs:
- Everolimus (RAD001): By mouth Daily 1-32
- Prednisone: By mouth or in the vein Three times daily on days 4-32
- Vincristine: In the vein Daily on days 4, 11, 18, and 25
- Doxorubicin: In the vein Once per day on days 4 and 5. A drug called dexrazoxane will be given with each dose of Doxorubicin to protect the heart from any damage that might be caused by Doxorubicin.
- PEG-asparaginase: In the vein Once per day on days 5 and 18
If you have or have had an allergy to PEG-asparaginase, we will give another form of asparaginase (Erwinia asparaginase). Four doses of Erwinia asparaginase will be given in the muscle twice a week beginning on Day 5 and then another 4 doses will be given in the muscle twice a week beginning on Day 15 in place of the scheduled doses of PEG-asparaginase.
In addition to the medications listed above, you will also be receiving intrathecal (IT) chemotherapy that is given directly into your spinal fluid to treat the leukemia that may have spread to your brain and spinal fluid. The medicines we will be giving in your spinal fluid are listed below. The number of times we give chemotherapy into the spinal fluid will depend on whether or not we see leukemia cells in your spinal fluid on the sample we take on the first day of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Months 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •ALL in first bone marrow relapse occuring > 18 months from initial diagnosis
- •Normal organ function
- •Maximum prior cumulative doxorubicin dose of </= 360 mg/m2 or equivalent
排除标准
- •Prior therapy for ALL except for intrathecal (IT) chemotherapy
- •Pregnant or lactating
- •Individuals whose relapsed ALL harbors a t(9;22)/BCR-ABL fusion
- •Individuals whose lymphoblasts have surface immunoglobulin by flow cytometry and/or t(8;14), t(2;8), or t(8;22)
- •Down syndrome
- •Prior stem cell transplant
- •History of asparaginase-associated pancreatitis
- •Active lung disease
- •Impairment of gastrointestinal function or gastrointestinal disease
- •Severe and/or uncontrolled intercurrent illness
- •Documented history of previous or current Hepatitis B or C infection
- •History of a different malignancy (other than ALL) unless disease-free for at 5 years and deemed by the investigators to be at low risk for recurrence of that malignancy
- •HIV positive on combination antiretroviral therapy
结局指标
主要结局
Safety and Feasibility
时间窗: 2 years
To determine the safety and feasibility of treatment with everolimus in combination with vincristine, prednisone, PEG-asparaginase and doxorubicin in patients with relapsed acute lymphoblastic leukemia (ALL)
次要结局
- Clinical Activity(2 years)
- Impact on biologic markers(2 years)
- Determinants of Response(2 years)
研究者
Lewis B. Silverman, MD
Principal Investigator
Dana-Farber Cancer Institute